These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 24825477)
21. Jitter analysis with concentric needle electrodes in the extensor digitorum communis for the diagnosis of myasthenia gravis: a pilot study. Wang J; Ji F; Luo B Chin Med J (Engl); 2014; 127(18):3209-12. PubMed ID: 25266514 [TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics and outcomes of myasthenia gravis patients with double positive antibodies against acetylcholine receptor and muscle-specific tyrosine kinase]. Lu YR; Yu L; Ma Q; Chen P; Qiu L; Ou CY; Lin ZZ; Liu WB Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):942-947. PubMed ID: 35385966 [No Abstract] [Full Text] [Related]
23. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981 [TBL] [Abstract][Full Text] [Related]
24. Single-fiber Electromyography in the Extensor Digitorum Communis for the Predictive Prognosis of Ocular Myasthenia Gravis: A Retrospective Study of 102 Cases. Guan YZ; Cui LY; Liu MS; Niu JW Chin Med J (Engl); 2015 Oct; 128(20):2783-6. PubMed ID: 26481746 [TBL] [Abstract][Full Text] [Related]
26. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638 [TBL] [Abstract][Full Text] [Related]
27. Different characteristic phenotypes according to antibody in myasthenia gravis. Oh SJ; Morgan MB; Lu L; Hatanaka Y; Hemmi S; Young A; Claussen GC J Clin Neuromuscul Dis; 2012 Dec; 14(2):57-65. PubMed ID: 23172384 [TBL] [Abstract][Full Text] [Related]
28. Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis. Takamori M; Nakamura T; Motomura M J Neuroimmunol; 2013 Jan; 254(1-2):183-6. PubMed ID: 22999188 [TBL] [Abstract][Full Text] [Related]
29. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539 [TBL] [Abstract][Full Text] [Related]
30. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study. Modoni A; Mastrorosa A; Spagni G; Evoli A Clin Neurophysiol; 2021 Aug; 132(8):1845-1849. PubMed ID: 34147009 [TBL] [Abstract][Full Text] [Related]